Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq-based transcriptome profiling of fruit extract of Brucea javanica (FEBJ) and cynaroside

ABSTRACT: Liver fibrosis is a wound-healing process that occurs in response to chronic liver injury. Traditional Chinese medicine (TCM) has been shown to have a significant effect on treating liver fibrosis. We found that the fruit extract of Brucea javanica (FEBJ) suppressed hepatic stellate cell (HSC) activation and extracellular matrix (ECM) deposition in vitro, and attenuated thioacetamide (TAA)- induced liver fibrosis in zebrafish. Moreover, we identified cynaroside as one of the active compounds of FEBJ that could reproduce its antifibrotic effects in vitro and in vivo. To further investigate the global transcriptome changes of FEBJ and cynaroside, RNA-seq was performed. The results indicated that FEBJ-regulated genes were involved mainly in ECM-remodeling related biological functions, and cynaroside-regulated genes were involved in various biological functions besides ECM-remodeling.

ORGANISM(S): Homo sapiens

PROVIDER: GSE266353 | GEO | 2025/03/12

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

A time-course study of thioacetamide (TAA)-induced liver fibrosis in rats

Project description:The aim is to characterize rat liver fibrosis induced by thioacetamide (TAA). To induce hepatic fibrosis, Male Sprague Dawley rats (9-12 weeks of age and 380-420 g of weight upon arrival, supplied by Beijing Vital River laboratory animal Co., Ltd.) were treated with thioacetamide (TAA). Rat liver samples were collected from five groups of rats at week 1, 2, 4, 8 and 13 after TAA (300 mg/kg) administration three times per week while five control groups receive the same volume of 0.9% normal saline. Four biological replicates were used for each group.

2021-09-29 | E-MTAB-10547 | biostudies-arrayexpress

Hepatic stellate cells isolated from PBS- or thioacetamide (TAA)-treated wild-type and Cyp1b1 knockout

Project description:Metabolomic analysis on hepatic stellate cells isolated from PBS- or thioacetamide (TAA)-treated wild-type and Cyp1b1 knockout mice was performed to determine the metabolic basis by which CYP1B1 ablation inhibits HSC activation and liver fibrosis.

2024-08-28 | MSV000095716 | MassIVE

Cytokine Priming Enhances the Antifibrotic Effects of Mesenchymal Stromal Cells Conditioned Medium Via Fibrogenic Myofibroblasts Elimination and Extracellular Matrix Degradation.

Project description:Fibrosis is a pathological scarring process characterized by persistent myofibroblasts activation with excessive accumulation of extracellular matrix (ECM). Fibrotic disorders represent an increasing burden of disease-associated morbidity and mortality worldwide for which there are limited therapeutic options. Reversing fibrosis requires the elimination of myofibroblasts, remodeling of the ECM, and regeneration of functional tissue. Multipotent mesenchymal stromal cells (MSC) have antifibrotic properties mediated by secreted factors present in their conditioned medium (MSC-CM). However, there are no standardized in vitro assays to predict the antifibrotic effects of human MSC, and, as a consequence, we lack evidence on the effect of cytokine priming on MSC’s antifibrotic effects. We hypothesize that the MSC-CM promotes fibrosis resolution in vitro and that this effect is enhanced following MSC cytokine priming.

2025-05-06 | PXD051586 | Pride

Rat transcriptomic profiling of liver sinusoidal endothelial cells during chronic liver disease reveals stage-specific secretory signature

Project description:RNAseq was applied to define the transcriptome of primary LSECs from rats with acute liver injury, mild liver fibrosis and advanced chronic liver disease (CLD) (due to CCl4 or thioacetamide administration). Results showed different transcriptomic profile during progression of CLD, and a large number of significant de-regulated genes (1412) were shared in cirrhotic CCl4- and TAA-LSECs (fold-change>1.5 and p-vale<0.05)compared with their respective healthy-LSECs.

2021-09-24 | GSE164878 | GEO

Prolyl endopeptidase-mediated transcriptional regulation in quiescent and activated bone marrow-derived macrophages (Bulk RNA-seq)

Project description:Liver fibrosis, a pathogical change commonly existing in various chronic liver diseases, can ultimately develop into life-threatening liver cirrhosis, but effective antifibrotic therapy is absent due to limited understanding of fibrogenic process. The characteristic fibrotic scar in fibrosis is stiff and disorganized extracellular matrix (ECM) yielded by ECM remodeling, a pathogenic process with vigorous participation of aberrantly activated macrophages. Prolyl endopeptidase (PREP) is a dipeptidyl peptidase that possess both proteolytic and non-proteolytic functions. Using Prep knockout mouse, we found aggravated liver fibrosis in a NASH-related fibrosis murine model, as well as significantly altered transcriptome by in vitro M1/M2 polarization in primary macrophages after PREP ablation. Most importantly, a PREP-mediated direct transcriptional regulation to active cis-regulatory genomic regions was identified for the first time as a novel non-proteolytic function of PREP, based on significant nuclear localization of PREP and CUT&Tag-seq results. Among the PREP-downstream genes, Ctsb and Ctsd, genes encoding ECM remodeling-related profibrogenic cathepsin B and D respectively, were excessively expressed in PREP-ablated macrophages in vitro and in vivo. Our results indicates that PREP is a newly found transcriptional regulator in macrophage, and is a promising therapeutic target for fibrosis-related aberrant macrophage activation.

2023-08-09 | GSE213050 | GEO

Prolyl endopeptidase-mediated transcriptional regulation in quiescent and activated bone marrow-derived macrophages (CUT&Tag)

2023-08-09 | GSE213049 | GEO

A time-course study of thioacetamide (TAA)-induced liver fibrosis in rats

Project description:A time-course study of thioacetamide (TAA)-induced liver fibrosis in rats

| PRJEB45544 | ENA

Spatiotemporal characterization of the cellular and molecular contributors to liver fibrosis in a murine hepatotoxic-injury model

Project description:The interplay between the inflammatory infiltrate and tissue resident cell populations (e.g. epithelial cells, fibroblasts and macrophages) invokes fibrogenesis. However, the temporal and mechanistic contributions of these cell populations to fibrosis remain poorly defined. To address this issue, liver inflammation, ductular reaction (DR) and fibrosis were induced in C57BL/6 mice by thioacetamide (TAA) administration for up to 12 weeks. TAA treatment induced two phases of liver fibrosis. A rapid peri-central inflammatory infiltrate enriched in F4/80+ monocytes co-localized with SMA+ myofibroblasts resulted in early collagen deposition, marking the start of an initial fibrotic phase (1-6 weeks). An expansion of bone marrow derived macrophages proceeded a second phase, characterized by accelerated progression of fibrosis (> 6 weeks) followed the migration of the DR from the portal tracts to the centrilobular site of injury, in association an increase in DR/macrophage interactions. Although CCL2 mRNA was rapidly induced in response to TAA, CCL2 deficiency only partially abrogated fibrosis. In contrast, CSF-1R blockade diminished CCR2neg (Ly6Clo) monocytes, attenuated the DR and significantly reduced fibrosis, illustrating the critical role of CSF-1 dependent monocyte/macrophage differentiation and linking the two phases of injury. We demonstrate that in response to liver injury, CSF-1 drives early monocyte mediated myofibroblast activation and collagen deposition, subsequent macrophage differentiation and their association with the advancing DR, the formation of fibrotic septa and the progression of liver fibrosis to cirrhosis.

2015-12-01 | GSE74605 | GEO

Auranofin prevents liver fibrosis by system Xc-mediated inhibition of NLRP3 inflammasome

Project description:Previous studies showed that the anti-rheumatic agent auranofin inhibits the NLRP3 inflammasome; thus, this study evaluate the anti-fibrotic effect of auranofin in vivo and explored the underlying molecular mechanism. The antifibrotic effect of auranofin is assessed in thioacetamide- and carbon tetrachloride-induced liver fibrosis models. In this study, we use RNA-sequencing in hepatic stellate cell (HSC), and bone marrow-derived macrophage (BMDM) to examine the underlying mechanism of auranofin.

2021-06-08 | GSE176346 | GEO

MiR-29a regulates liver fibrosis

Project description:To confirm the mechanism of miR-29a in liver fibrosis healing, we have employed whole genome microarray expression profiling as a discovery platform to identify genes. CCl4 and TAA liver fibrosis model mouse were used for this experiment. After five weeks liver fibrosis induction period, mouse have been observed for one week (1w) or two weeks (2w) and negative control nucleotide (N.C) or miR-29a were injected every 3 days on this period. We used CCl4 1w N.C (n = 1), 1w miR-29a (n = 1), 2w N.C (n = 1), 2w miR-29a (n = 1), and also used TAA model mouse (total n = 8) liver samples for microarray analysis. We can get only one gene (PDGF-c) as a target of miR-29a which relate to liver fibrosis and down-regulated more than 1.5 times in common miR-29a injected group than N.C group. CCl4 and TAA liver fibrosis model mouse were used for this experiment. After five weeks liver fibrosis induction period, mouse have been obserbed for one week (1w) or two weeks (2w) and negative control nucleotide (N.C) or miR-29a were injected every 3 days on this period. We used CCl4 1w N.C (n = 1), 1w miR-29a (n = 1), 2w N.C (n = 1), 2w miR-29a (n = 1), and also used TAA model mouse (total n = 8) liver samples for microarray analysis.

2015-03-31 | E-GEOD-67423 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data